Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs

Clinical Trials

Volumn 6, Issue 3, 2009, Pages 239-251

  Pogue, Janice ^a,b   Walter, Stephen D ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; ENOXAPARIN; FOLIC ACID; FONDAPARINUX; HEPARIN; HIRUDIN; PLACEBO; RAMIPRIL; REVIPARIN;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; EVENT ADJUDICATION; HEART INFARCTION; HUMAN; MASKED CLINICAL TRIAL; META ANALYSIS; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RISK; SENSITIVITY ANALYSIS; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; THERAPY EFFECT; UNMASKED CLINICAL TRIAL; VASCULAR DISEASE;

CANADA; CARDIOVASCULAR DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67649383249     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774509105223     Document Type: Article

References (30)

1. Walter SD, Cook DJ, Guyatt GH, King D., Troyan S. (for the Canadian Lung Oncology Group). Outcome assessment for clinical trials: How many adjudicators do we need? Control Clin Trials 1997; 18: 27-42.
2. Sicurella J., Roberts R., Gent M. The operation of a central adjudication committee and its effect on the validity of the assessment of treatment benefit. Control Clin Trials 1990; 11: 283.
3. Eisenbud R., Assman SF, Kalish LA et al. Differences in difficultly adjudicating clinical events in patients with advanced HIV disease (for the Viral Activation Transfusion Study (VATS) Group). J Immune Defic Syndr 2001; 28: 43-6.
4. Canner PL, Krol WF, Forman SA External quality control programs. Control Clin Trials 1983; 4: 441-66.
5. Cook DJ, Walter SD, Cook RJ et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998; 129: 433-40.
6. Mahaffey KW, Harrington RA, Akkerhuis M. et al. (for the PURSUIT Investigators). Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med 2001; 2: 180-86.
7. Mahaffey KW, Roe MT, Dyke CK et al. (for the PARAGON-B Investigators). Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J 2002; 143: 242-48.
8. Vejlstrup N., Clemmensen P., Steinmetz E. et al. (on behalf of the DANAMI-2 investigators). Blinded end point adjudication in the 'Danish Multicenter Randomized Study on Fibrinolytic Therapy versus Acute Coronary Angioplasty in Acute Myocardial Infarction' (DANAMI-2 trial). Heart Drug 2003; 3: 127-33.
9. Petersen JL, Haque G., Hellkamp AS et al. (MOST Clinical Events Committee). Comparing classifications of death in the Mode Selection Trial: Agreement and disagreement among site investigators and a clinical events committee. Contemp Clin Trials 2006; 27: 260-68.
10. Naslund U., Grip L., Fischer-Hansen J. et al. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: Results with and without the end-point committee's final decision on end-points. Eur Heart J 1999; 20: 771-7.
11. Granger CB, Vogel V., Cummings SR et al. Do we need to adjudicate major clinical events? Clin Trials 2008; 5:56- 60.
12. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention - IMPACT-II. Lancet 1997; 349: 1422-8.
13. The GUSTO-Iib Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
14. Yusuf S., Pfeffer MA, Swedberg K. et al. (CHARM Investigators and Committees). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777-81.
15. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Iib/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
16. Organization to assess strategies for ischemic syndromes (OASIS) investigator. A pilot study to assess the effects of two doses of recombinant hirudin compared to heparin in patients with acute myocardial ischemia without ST elevation. Circulation 1997; 96: 769-77.
17. Anand S., Yusuf S., Pogue J., Weitz J., Flather M. (for the OASIS Pilot Study Investigators). Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q wave MI: Organization to Assess Strategies for Ischemic Syndomes (OASIS) pilot study results. Circulation 1998; 98: 1064-70.
18. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high- risk patients. N Engl J Med 2000; 342(3): 145-53.
19. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial. Lancet 1999; 353: 429 - 38.
20. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
21. Yusuf S., Mehta SR, Xie C. et al. (CREATE Trial Group Investigators). Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. J Am Med Assoc 2005; 293: 427-35.
22. Lonn E., Yusuf S., Arnold MJ et al. (Heart Outcomes Evaluation (HOPE) 2 Investigators). Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
23. Yusuf S., Mehta SR, Chrolavicius S. et al. (Fifth Organization to Assess Strategies in Acute Ischemic Syndrome Investigators). Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-76.
24. Yusuf S., Mehta SR, Chrolavicius S. et al. (OASIS-6 Trial Group). Effect of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-30.
25. Connolly S., Pogue J., Hart R. et al. (ACTIVE Writing Group on behalf of the ACTIVE Investigators). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomized controlled trial. Lancet 2006; 367: 1903-12.
26. Anand S., Yusuf S., Xie C. et al. (Warfarin Antiplatelet Vascular Evaluation Trial Investigators). Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-27.
27. SAS Institute Inc. SAS 9.1. Cary, NC: SAS Institute Inc; 2002.
28. White HD, Aylward PE, Huang Z. et al. (VALIANT Investigators). Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: Results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005; 112: 3391-9.
29. Solomon SD, Wang D., Finn P. et al. Effect of candesartan on cause-specific mortality in heart failure patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110: 2180-3.
30. The ALLHAT officers, & Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.